Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab in chronic kidney disease with inflammation
NCT03926117Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ziltivekimab in chronic kidney disease (CKD) (4 arms), sponsored by Novo Nordisk. Primary endpoint: High-sensitivity C-reactive Protein at 13 weeks. Started Jun 2019; status: completed.
02
Drugs
ziltivekimab
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03926117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926117.